Savara shares are trading higher after the company announced the Phase 3 IMPALA-2 clinical trial met its primary endpoints and multiple scondary endpoints.
Portfolio Pulse from Benzinga Newsdesk
Savara shares are trading higher following the announcement of positive results from the pivotal, Phase 3 IMPALA-2 clinical trial.
June 26, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Savara shares are experiencing an upward trend due to the positive outcomes from the Phase 3 IMPALA-2 clinical trial.
The positive results from the Phase 3 IMPALA-2 clinical trial are a significant milestone for Savara, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100